1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsPAR-25-374: Translational Bioinformatics and Experimental Approaches to Advance Drug Repositioning and Combination Therapy Development for Alzheimer's Disease and Related Dementias (R01 Clinical Trial Not Allowed) is sponsored by National Institutes of Health (NIH). Supports research on bioinformatics and experimental approaches for drug repositioning and combination therapy in Alzheimer's disease.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Translational Bioinformatics and Experimental Approaches to Advance Drug Repositioning and Combination Therapy Development for Alzheimers Disease and Related Dementias (R01 Clinical Trial Not Allowed) Grant Posted Discretionary Translational Bioinformatics and Experimental Approaches to Advance Drug Repositioning and Combination Therapy Development for Alzheimers Disease and Related Dementias (R01 Clinical Trial Not Allowed) National Institutes of Health AI Analysis Solicitation Details Details Grant Documents ( 2 ) Documents ( 2 ) Grant Opportunity Analysis The National Institutes of Health (NIH) is offering a funding opportunity aimed at advancing drug repositioning and combination therapy development for Alzheimer's Disease (AD) and related dementias (ADRD).
This initiative invites applications that utilize mouse models to conduct rigorous preclinical testing of FDA-approved drugs or investigational compounds, with the goal of establishing proof of concept for effective treatment strategies.
Given the historical challenges in developing successful AD therapies, this program emphasizes a systematic approach and encourages collaboration between academia and industry to enhance research rigor and reproducibility. Applicants may receive up to $1 million annually, with a total funding pool of $6 million available for 4-5 awards.
The application deadline is May 7, 2028, and interested parties can reach out to NIH Grants Information at grantsinfo@nih. gov for further inquiries.
Additional Eligibility Information Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
PAR-25-374-Full-Announcement. html No AI summary available for this file. The Department of Health and Human Services, through the National Institutes of Health (NIH), announces a funding opportunity for projects focused on advancing drug repositioning and combination therapy development for Alzheimer's Disease (AD) and related dementias (ADRD).
The initiative invites applications that utilize computational and experimental approaches to rigorously test FDA-approved drugs or investigational compounds currently misappropriated for other conditions, aimed at demonstrating efficacy for AD/ADRD. The goal is to support in-vivo and in-vitro proof-of-concept studies to establish synergies and optimize therapeutic strategies.
While drug repurposing has potential advantages like reduced development costs and timeframes, previous efforts in AD treatments have been largely unsuccessful, underlining the need for a more systematic approach. The program encourages collaborative partnerships between academia and industry, and emphasizes compliance with NIH policies for research rigor and reproducibility.
Applications can receive up to $1 million annually, with a funding pool of $6 million intended for 4-5 awards. The application process has defined deadlines and submission requirements designed to ensure thorough review and compliance with open research practices, stressing the importance of data management and sharing throughout the project lifespan.
Related Grant Opportunities View Documents Access 2 attachments posted Original Opportunity Posted Dec 30, 2024 deadline Application Deadline May 7, 2028 expiry Archive Date Jun 12, 2028 Est. Total Program Funding $1,000,000 Agency National Institutes of Health ( HHS-NIH11 )
According to the current listing, eligibility includes: Universities, Nonprofits, For-profit organizations, Small businesses. Confirm the full requirements in the official notice before applying.
PAR-25-374: Translational Bioinformatics and Experimental Approaches to Advance Drug Repositioning and Combination Therapy Development for Alzheimer's Disease and Related Dementias (R01 Clinical Trial Not Allowed) is funded by National Institutes of Health (NIH). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
PA-27-037 consolidates the Predoctoral to Postdoctoral Transition Award into a single parent announcement across 20 NIH components, with the next deadline December 8, 2026. The eligibility gate is not the science — it is a mandatory change of institution and mentor between the F99 and K00 phases.
Read articleA draft executive order would have put OMB Director Russell Vought on a commission with final say over NIH awards after peer review. Sen. Collins killed it by pointing at a provision Congress already passed. Here is what the episode teaches applicants about the December 11 cliff.
Read articlePA-27-034, PA-27-035 and PA-27-036 replace the institute-specific R25 announcements that research education programs have been built around for a decade. NCI, NIDA and NIGMS have already expired theirs early. Here is what the consolidation actually changes: an 8% indirect cost ceiling, a US-citizens-and-permanent-residents participant rule, a cooperative agreement variant that only exists on one of the three, and no clinical-trial-allowed companion anywhere.
Read article